H.C. Wainwright維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價22美元
JonesTrading維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價45美元
EyePoint pharmaceuticals的目標價格由HC Wainwright & Co.維持在每股22.00美元。
eyepoint pharmaceuticals 分析師評級
JonesTrading維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價45美元
貝雅維持EyePoint Pharmaceuticals(EYPT.US)買入評級,下調目標價至33美元
JonesTrading維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價45美元
H.C. Wainwright維持EyePoint Pharmaceuticals(EYPT.US)買入評級,下調目標價至22美元
eyepoint pharmaceuticals被HC Wainwright和Co維持在買入
eyepoint pharmaceuticals股價目標由HC Wainwright & Co. 降至$22.00/股,原價爲$30.00
Chardan Capital維持對eyepoint pharmaceuticals的買入評級,並將目標股價上調至33美元
TD Cowen維持EyePoint Pharmaceuticals(EYPT.US)買入評級,下調目標價至20美元
eyepoint pharmaceuticals:臨床試驗進展及有望的中期數據推動了買入評級
豐業銀行維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價18美元
eyepoint pharmaceuticals被Chardan Capital維持爲買入
eyepoint pharmaceuticals 分析師評級
第一資本維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價35美元
JonesTrading首次給予EyePoint Pharmaceuticals(EYPT.US)買入評級,目標價45美元
貝雅維持EyePoint Pharmaceuticals(EYPT.US)買入評級,維持目標價38美元
eyepoint pharmaceuticals分析師評級